MAIA Biotechnology, Inc. (MAIA) Stock: Dividends & Earnings

Company Overview:

Market Cap: $71.13M

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $0.87 - $3.19

4.2 Year MAIA Performance Metrics:

Total Return (with DRIP): -73.8% (-27.28% CAGR)

Total Return (no DRIP): -73.8% (-27.28% CAGR)

Share Price: -73.8% (-27.28% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $2,623

Total Return $ (with DRIP): -$7,377

MAIA Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

MAIA Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Projected Future Returns & Dividends for MAIA

Based on past 4.2-year performance, here are MAIA growth metrics:

Share price CAGR of -27.28%
Dividend CAGR of +0%

Using MAIA CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	MAIA (DRIP)	MAIA - No DRIP
Current Price	$1.17	$1.17
Start Shares	8,547.01	8,547.01
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	8,547.01	8,547.01
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$0.05	$1.17
Total Dividends	$0	$0
Final Value	$413	$10,000

Estimated Future Value + Dividends - MAIA

NOTE: Above numbers are our estimate based on MAIA's Dividend and Price CAGR over past 4.2 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

MAIA Biotechnology, Inc. (MAIA) had its IPO on , and is traded on NYSE stock exchange.

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. MAIA Biotechnology concentrates on oncology programs designed to address telomerase-positive cancers, with its lead asset, ateganosine (THIO), an investigational telomere-targeting agent in clinical development for non-small cell lung cancer. The company’s work centers on novel mechanisms of action that combine telomere targeting with immunogenic effects, reflecting a precision-medicine approach to difficult-to-treat tumors. MAIA Biotechnology also advances related second-generation telomere-targeting candidates as part of its current research pipeline. Headquartered in Chicago, Illinois and founded in 2018, MAIA Biotechnology operates within the biotechnology sector and plays a specialized role in the cancer therapeutics market by developing experimental treatments intended for use in oncology and immuno-oncology settings.

MAIA website: https://maiabiotech.com